U.S. Patent and Trademark Office Approves Patent Application That Extends Advaxis Technology to Include HER2/neu for …
U.S. Patent and Trademark Office Approves Patent Application That Extends Advaxis Technology to Include HER2/neu for …
NORTH BRUNSWICK, N.J.—-The U.S. Patent and Trademark Office has approved Advaxis, Inc., , the live, attenuated Listeria monocytogenes immunotherapy company, intellectual property protection to patent application 11/223,945 a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu , when using the company s proprietary listeriolysin O fusion platform …